17-Apr-2026
IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates
Globe Newswire (Thu, 16-Apr 9:00 AM ET)
Globe Newswire (Wed, 15-Apr 5:25 PM ET)
Globe Newswire (Tue, 14-Apr 5:08 PM ET)
Newsfile (Fri, 10-Apr 10:36 PM ET)
PRNewswire (Thu, 9-Apr 5:36 PM ET)
Globe Newswire (Fri, 3-Apr 10:00 PM ET)
Newsfile (Sun, 29-Mar 10:58 PM ET)
Market Chameleon (Tue, 17-Feb 5:33 AM ET)
Disc Medicine Secures Accelerated NDA Review and Eyes Multiple Clinical Milestones for 2026
Market Chameleon (Mon, 12-Jan 3:49 AM ET)
Disc Medicine’s $250 Million Upsized Public Offering Bolsters Plans for Hematology Pipeline
Market Chameleon (Tue, 21-Oct 4:27 AM ET)
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Disc Medicine trades on the NASDAQ stock market under the symbol IRON.
As of April 17, 2026, IRON stock price climbed to $71.77 with 259,783 million shares trading.
IRON has a beta of 1.48, meaning it tends to be more sensitive to market movements. IRON has a correlation of 0.13 to the broad based SPY ETF.
IRON has a market cap of $2.71 billion. This is considered a Mid Cap stock.
In the last 3 years, IRON traded as high as $99.50 and as low as $23.30.
The top ETF exchange traded funds that IRON belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
IRON has outperformed the market in the last year with a price return of +70.2% while the SPY ETF gained +36.3%. However, in the short term, IRON had mixed performance relative to the market. It has underperformed in the last 3 months, returning +1.2% vs +2.9% return in SPY. But in the last 2 weeks, IRON shares have fared better than the market returning +10.1% compared to SPY +8.3%.
IRON support price is $67.50 and resistance is $71.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRON shares will trade within this expected range on the day.
